Mechanism of Action Video of Anabasum

View Video

Profile

Business Description

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in Phase 2 studies in diffuse cutaneous systemic sclerosis, cystic fibrosis and dermatomyositis. Additionally, the Company is evaluating anabasum in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis. The Company expects to commence a Phase 2 study in systemic lupus erythematosus, a Phase 3 study in systemic sclerosis and a Phase 2b study in cystic fibrosis in the fourth quarter of 2017.

Company Info

Address:
100 River Ridge Drive
Suite 103
Norwood, MA 02062 US

Telephone:
617.963.0100

Fax:
617.663.6085

Email:
info@corbuspharma.com

Industry Classifications

Sector:
Biopharmaceutical

Industry:
Biotechnology

NAICS:
325412 – Pharmaceutical Preparation Manufacturing

SIC:
2834 – Pharmaceutical Preparations